J.Safra Asset Management Corp Ascendis Pharma A/S Transaction History
J.Safra Asset Management Corp
- $1.54 Billion
- Q3 2025
A detailed history of J.Safra Asset Management Corp transactions in Ascendis Pharma A/S stock. As of the latest transaction made, J.Safra Asset Management Corp holds 61 shares of ASND stock, worth $12,426. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61
Previous 90
32.22%
Holding current value
$12,426
Previous $15,000
20.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ASND
# of Institutions
283Shares Held
60MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.09 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.12 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$1.01 Billion15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$902 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$867 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...